Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04265053 · ClinicalTrials.gov registry record · Early Phase 1
Human Cerebral Blood Flow Regulation
A Early Phase 1 study, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 42
- Enrollment target
NCT04265053 is a Early Phase 1 study that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 42 participants.
The verdict
NCT04265053, a Early Phase 1 study, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
To determine cerebrovascular control mechanisms in humans and provide mechanistic knowledge to offer new sex-specific therapeutic options for cerebrovascular diseases. The current objective is to determine how sex and sex hormones influence CBF control in healthy young adults without confounds of age or disease. The central hypothesis is men exhibit reduced cerebral vasodilator function due in part to differences in COX signaling compared to women. Comprehensive CBF data from multi-modal MRI indicate the magnitude of sex differences-as well as the vasodilator mechanisms-are regionally distinct. Research confounding variables like aging and disease will be mitigated by comparing younger adults (18-40 years old).
Interventions
- DRUG Indomethacin 25 MG/50 MG
- DRUG Placebo - Lactose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2021-04-12 |
| Est. Completion | 2025-05-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04265053
The ClinicalTrials.gov registry entry for NCT04265053 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Indomethacin 25 MG/50 MG is the first listed.
NCT04265053 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04265053 about?
NCT04265053 is a clinical study titled "Human Cerebral Blood Flow Regulation". To determine cerebrovascular control mechanisms in humans and provide mechanistic knowledge to offer new sex-specific therapeutic options for cerebrovascular diseases. The current objective is to determine how sex and sex hormones influence CBF control in healthy young adults without confounds of ag...
What is the current status of trial NCT04265053?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 42 participants. The study started on 2021-04-12. Estimated completion is 2025-05-31.
What interventions are being tested in trial NCT04265053?
The interventions under investigation include: Indomethacin 25 MG/50 MG (DRUG), Placebo - Lactose (DRUG).
Who is sponsoring clinical trial NCT04265053?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.